Related Experiment Video
Updated: Jun 24, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis
Angela D Armendariz1, Ronald M Krauss
1Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
Genetic factors influence C-reactive protein (CRP) levels, a marker for coronary heart disease risk. Hepatic nuclear factor (HNF) 1-alpha plays a key role in CRP gene regulation and links metabolic and inflammatory pathways.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Disease
Background:
- Elevated C-reactive protein (CRP) levels are associated with increased coronary heart disease (CHD) risk.
- Understanding CRP regulation is crucial for comprehending its role in CHD pathogenesis.
- Genetic determinants of CRP levels are of significant interest.
Purpose of the Study:
- To review recent findings on genetic factors influencing plasma CRP levels.
- To explore the role of hepatic nuclear factor (HNF) 1-alpha in CRP regulation.
- To understand the link between HNF1-alpha, CRP, and CHD.
Main Methods:
- Review of recent genetic association studies.
- Analysis of single nucleotide polymorphisms (SNPs) related to CRP levels.
- Examination of the molecular mechanisms of HNF1-alpha in CRP gene expression.
Main Results:
- Genome-wide association studies identified SNPs near the HNF1A gene associated with CRP levels.
- The CRP gene promoter contains HNF1-alpha-binding sites.
- HNF1-alpha is essential for cytokine-induced CRP expression, involving STAT3 and c-Fos.
Conclusions:
- HNF1-alpha is a key regulator of CRP gene expression.
- HNF1-alpha may link metabolic and inflammatory pathways in CHD.
- Genetic variations in HNF1A could influence CHD risk through CRP modulation.
Related Concept Videos
Atherosclerosis I: Introduction
Cirrhosis II: Pathophysiology
Inflammation
Chronic Pancreatitis II: Pathophysiology
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets